A naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. One of the most studied peptides in dermatology for skin repair, anti-aging, and wound healing.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that binds copper(II) with high affinity. It was first identified in human plasma by Dr. Loren Pickart in 1973, where it was found to stimulate liver cells to synthesize proteins at a rate similar to young tissue.
GHK-Cu is one of the few therapeutic peptides with substantial human clinical data supporting its topical use. It naturally declines with age — plasma levels drop from ~200 ng/mL at age 20 to ~80 ng/mL by age 60 — and this decline correlates with reduced wound healing capacity and skin aging.
At just 3 amino acids (Gly-His-Lys), GHK-Cu is the smallest therapeutically active peptide in this encyclopedia. Its copper-binding ability comes from the histidine imidazole ring (primary Cu²⁺ coordination) and the glycine amino group (secondary coordination). The lysine provides a positive charge that may aid cell membrane interaction.
GHK-Cu's mechanism is unique among therapeutic peptides because it operates through both gene regulation (the peptide component) and enzymatic cofactor delivery (the copper component). Genome-wide studies show GHK-Cu modulates the expression of over 4,000 genes, with a net effect of resetting gene expression patterns toward a younger, more regenerative state.
| Pathway | Effect | Significance |
|---|---|---|
| Collagen synthesis | Upregulates collagen type I, III, and V gene expression | Increases dermal thickness and mechanical strength |
| Lysyl oxidase activation | Cu²⁺ is an essential cofactor for LOX | Cross-links collagen and elastin fibers for structural integrity |
| Glycosaminoglycan synthesis | Stimulates decorin, heparan sulfate, and hyaluronic acid production | Improves skin hydration and extracellular matrix quality |
| Anti-inflammatory | Suppresses IL-6, TNF-α; blocks thromboxane formation | Reduces inflammation without immunosuppression |
| Antioxidant | Induces superoxide dismutase (SOD) and other antioxidant enzymes | Protects newly forming tissue from oxidative damage |
GHK-Cu has one of the stronger clinical evidence bases among therapeutic peptides, particularly for topical skin applications.
| Study Area | Design | Key Findings | Evidence |
|---|---|---|---|
| Facial skin remodeling | Double-blind RCT, n=67 women | Topical GHK-Cu cream improved skin density, thickness, and reduced wrinkles vs placebo after 12 weeks | Level I-II |
| Wound healing | Clinical studies, various wounds | Accelerated wound closure in surgical and chronic wounds; improved cosmetic outcome | Level II |
| Hair growth | Clinical pilot, alopecia | Increased hair follicle size and growth rate; comparable to minoxidil in some measures | Level II-III |
| Post-laser resurfacing | Clinical study | Faster healing and reduced erythema after fractional laser treatment | Level II |
| Gene expression | In vitro, genome-wide analysis | Modulated 4,000+ genes with net shift toward regenerative/anti-inflammatory profile | Preclinical |
Excellent topical safety: Decades of cosmetic use with no significant adverse effects reported. Generally recognized as safe for topical application.
Allergic reactions: Rare contact dermatitis reported in sensitive individuals. Patch testing recommended.
Copper toxicity (theoretical): Excessive systemic copper is toxic (Wilson's disease). Topical GHK-Cu delivers negligible systemic copper, but injectable use should be monitored.
Not for copper-sensitive conditions: Contraindicated in Wilson's disease or known copper hypersensitivity.
| Jurisdiction | Status |
|---|---|
| FDA | Not approved as a drug. Used as a cosmetic ingredient (INCI: Copper Tripeptide-1). |
| Cosmetic industry | Widely used in premium skincare products (serums, creams, masks) |
| WADA | Not banned |